Literature DB >> 10212502

Treatment of in-stent restenosis.

G S Mintz1, R Mehran, R Waksman, A D Pichard, K M Kent, L F Satler, M B Leon.   

Abstract

Although in-stent restenosis is the result of neointimal hyperplasia, mechanical problems (e.g. stent underexpansion) that occurred during implantation may result in restenosis at follow-up. The treatment of in-stent restenosis, begins with identification of these occult mechanical problems. Thereafter, in-stent restenosis can be treated with PTCA, atheroablation, or additional stent implantation; it is nuclear which technique is superior. Not all in-stent restenosis lesions have a similar risk of recurrence. Recurrence appears to depend on several markers of biologic activity: focal vs diffuse in-stent restenosis, the first episode vs recurrent in-stent restenosis, and early vs late recurrence. Vascular brachytherapy has emerged as the most promising way to treat high-risk lesion subsets.

Entities:  

Mesh:

Year:  1998        PMID: 10212502

Source DB:  PubMed          Journal:  Semin Interv Cardiol        ISSN: 1084-2764


  3 in total

Review 1.  Role of stenting in coronary revascularisation.

Authors:  A H Gershlick
Journal:  Heart       Date:  2001-07       Impact factor: 5.994

2.  The viral anti-inflammatory chemokine-binding protein M-T7 reduces intimal hyperplasia after vascular injury.

Authors:  L Liu; A Lalani; E Dai; B Seet; C Macauley; R Singh; L Fan; G McFadden; A Lucas
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

3.  Rationale and design of the randomized, multicenter, cilostazol for RESTenosis (CREST) trial.

Authors:  John S Douglas; William S Weintraub; David Holmes
Journal:  Clin Cardiol       Date:  2003-10       Impact factor: 2.882

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.